Conference calendar

16–19 May

EuroPCR 2023 Paris, France pcronline.com

18–20 May

Society for Cardiovascular Angiography and Interventions (SCAI) 2023 Scientific Sessions Phoenix, USA scai.org/education-and-events

Abbott and Cardiovascular Systems (CSI) have announced a definitive agreement for Abbott to acquire CSI. Under terms of the agreement, CSI stockholders will receive US$20 per common share at a total expected equity value of approximately US$890 million.

CSI is a leader in devices for atherectomy, the procedural use of which can help maximise the benefits of standard balloon angioplasty or stent treatments in restoring blood flow in complex arterial disease. CSI also has an early-stage pipeline of complementary vascular intervention devices in development.

“The acquisition of CSI will add new, complementary technologies to Abbott’s leading vascular device offerings,” said Lisa Earnhardt, executive vice president, Medical Devices, Abbott.“We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialisation of innovative solutions for treating complex peripheral vascular disease and coronary artery disease,” said Scott Ward, CSI’s chairman, president, and chief executive officer.

Upon closing, the transaction is expected to be neutral to Abbott’s recently issued 2023 ongoing earnings per share guidance.

The transaction, which has been approved by the boards of directors of CSI and Abbott, is subject to the approval of CSI stockholders and the satisfaction of customary closing conditions, including applicable regulatory approvals.

JP Morgan Securities LLC is serving as financial advisor to CSI.

7–10 June The Structural Heart Summit (TVT) Phoenix, USA tvt.crfconnect.com

14 – 15 July Interventional Complications 2023 Seattle, USA complications2023.crfconnect.com

25–28 August European Society of Cardiology (ESC) Congress Amsterdam, The Netherlands escardio.org

The company credits Latib with having played a key role in the development of its novel percutaneous ventricular assist device (pVAD) technology, previously serving as a clinical advisor and attending the initial first-in-human cases. Latib will retain his current position as the section head of Interventional Cardiology and director of Structural Heart Interventions at Montefiore Health Systems.

“I am very excited to join the Supira team and believe it has an excellent offering with one system designed to support cardiovascular haemodynamics for both high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS) patients,” stated Latib. “The unique pump is designed to achieve the required high continuous flow without the risk of bleeding often associated with these types of devices. This will advance clinical practice and enable more physicians to confidently perform these procedures.”

Latib’s professional expertise focuses on complex coronary interventions and structural heart disease, as well as a passion for new device innovation, Supira Medical said in a press release. He has authored over 700 peerreviewed articles and serves on the editorial board for several publications including the Journal of American College of Cardiology (JACC), Cardiovascular Revascularization Medicine and EuroIntervention. Latib is a member of several professional organisations including the American College of Cardiology (ACC) and the European Society of Cardiology (ESC).

HeartBeam, a cardiac technology company that has developed the three-dimensional (3D)-vector electrocardiogram (VECG) platform for heart attack detection has announced the strategic acquisition of all assets from LIVMOR, a digital health solutions company providing a patientengaging remote monitoring system of critical physiological biomarkers. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing US Food and Drug Administration (FDA)cleared product.

Founded in 2016, LIVMOR developed the Halo+ atrial fibrillation (AF) detection system, which they believe to be the first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The Halo system provides continuous monitoring of pulse rhythms for the detection of AF on-demand during the day and automatically overnight. LIVMOR’s technology was commercially deployed within the Veteran Affairs Healthcare System in Dallas, USA.

In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR’s FDA-cleared Halo cloudbased software platform to connect physicians and patients. Utilising the Halo cloud-based platform allowed HeartBeam to meet its schedule for FDA submission of the HeartBeam AIMI software for acute care settings that provides a VECG comparison of baseline and symptomatic 12-lead electrocardiogram (ECG) to more accurately identify a heart attack.

Under the terms of the acquisition agreement, HeartBeam purchased LIVMOR’s intellectual property for an undisclosed amount, including three issued USA patents, LIVMOR technology, including the Halo AF detection system, LIVMORs business contracts and relationships as well as all Samsung watch and tablet inventory. Additionally, HeartBeam hired LIVMOR’s key technical employees.

7–10 November Cardiovascular Interventions La Jolla, USA cvinterventions.com

27–29 January 2024 Society of Thoracic Surgery (STS) Annual Meeting San Antonio, USA sts.org/meetings

4–7 October European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting Vienna, Austria eacts.org/annual-meeting

23–26 October TCT 2023 San Francisco, USA tct2023.crfconnect.com

11–13 November

American Heart Association (AHA) 2023 Scientific Sessions Philadelphia, USA professional.heart.org

19–21 November PCR London Valves 2023 London, UK pcronline.com/courses

9–12 March 2024

Cardiovascular Research Technologies (CRT) 2024 Washington DC, USA crtmeeting.org